Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
-
Published:2024-06
Issue:3
Volume:22
Page:102075
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Tashiro KojiroORCID,
Kimura Shoji,
Tsuzuki Shunsuke,
Urabe Fumihiko,
Fukuokaya Wataru,
Mori KeiichiroORCID,
Aikawa Koichi,
Murakami Masaya,
Sasaki Hiroshi,
Miki Kenta,
Miki Jun,
Shimomura Tatsuya,
Yamada Hiroki,
Hata Kenichi,
Nishikawa Hideomi,
Abe Hirokazu,
Watanabe Ken,
Kimura TakahiroORCID
Reference28 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
2. Contemporary trends in the incidence of metastatic prostate cancer among US men: results from nationwide analyses;Dalela;Eur Urol Focus,2019
3. Mariotto A.,et al. Annual Report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics;Negoita;Cancer,2018
4. Carducci M.,et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
5. Stockler M.R.,et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N Engl J Med,2019